Puts puts puts baby
08-27

While the $9.2B peak sales model for intismeran provides strong long-term validation for Moderna’s mRNA platform beyond COVID-19, chasing a 14% single-day pop driven by a broker upgrade from Underperform to Neutral carries high near-term risk. Without published Phase 3 trial specifics or signed commercial contracts, current pricing reflects speculative future potential while LTM revenue remains down 27.6% y/y at $2.23B. The safer play is rotating into Merck, which split-funds the therapy and provides immediate downside protection via Keytruda cash flows, or simply waiting for detailed clinical data before building a core position in Moderna.

Phase 3 Leak Hits Moderna: Did Expectations Outrun the Science?
Moderna fell 17.57% after Phase 3 results for its personalized cancer vaccine with Merck leaked early. In over 1,100 melanoma patients, intismeran plus Keytruda cut recurrence-or-death risk 42% and distant-metastasis-or-death risk 38%, with no new safety signals. Bulls see mRNA-platform validation; bears say expectations were higher and other cancers remain untested. What evidence would show the platform works beyond a single indication?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment